by John Conrad | Apr 24, 2026 | Policy News
Statement from John Conrad, President & CEO, iBIO “The FDA’s recent announcement advancing a more predictable Medicare coverage pathway for breakthrough medical technologies marks an important step toward addressing one of the most persistent challenges in patient...
by John Conrad | Nov 20, 2025 | iBIO News
Illinois’ life sciences industry is entering one of the most promising periods in its history. Today, more than 93,000 Illinoisans work in biosciences, earning an average annual wage of $153,000—a figure that speaks not only to the sophistication of these roles but...
by John Conrad | Nov 20, 2025 | Member News
It was exciting to see Dimension Bio featured in Fast Company this week — a national spotlight that underscores just how far this Chicago-born biotech has pushed the boundaries of regenerative medicine. The profile traces the company’s journey from its early work in...
by John Conrad | Aug 5, 2025 | iBIO News
Report highlights nearly 100 life science companies and investment trends as Chicago prepares to welcome BIO International Convention 2030 CHICAGO, IL – August 5, 2025 – The Illinois Biotechnology Innovation Organization (iBIO) today released its inaugural Member...
by John Conrad | Aug 1, 2025 | Member News, NewsBrief
Chicago biotech startup ClostraBio has secured GRAS (Generally Recognized as Safe) status for its flagship probiotic ingredient CLB101™, clearing the path for the first commercially available strain of Anaerostipes caccae in the U.S. What Makes It Different Unlike...
